These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35884501)

  • 41. Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors
    Liu S; Geng S; Shi N; Zhang L; Xue W; Li Y; Jiang K
    Front Pharmacol; 2022; 13():878540. PubMed ID: 35401171
    [No Abstract]   [Full Text] [Related]  

  • 42. Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China.
    Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
    Front Oncol; 2022; 12():859938. PubMed ID: 35392244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
    Bai R; Li L; Chen X; Chen N; Song W; Zhang Y; Lv Z; Han F; Zhao Y; Li W; Cui J
    J Oncol; 2021; 2021():9935076. PubMed ID: 34335763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
    Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Xie M; Yu X; Chu X; Xie H; Zhou J; Zhao J; Su C
    Thorac Cancer; 2022 Feb; 13(3):353-360. PubMed ID: 34962050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients.
    Jiang S; Geng S; Chen Q; Zhang C; Cheng M; Yu Y; Zhang S; Shi N; Dong M
    Front Oncol; 2022; 12():823705. PubMed ID: 35223505
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer.
    Ge X; Zhang Z; Zhang S; Yuan F; Zhang F; Yan X; Han X; Ma J; Wang L; Tao H; Li X; Zhi X; Huang Z; Hofman P; Prelaj A; Banna GL; Mutti L; Hu Y; Wang J
    Transl Lung Cancer Res; 2020 Dec; 9(6):2391-2400. PubMed ID: 33489801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
    Fan Y; Xie W; Huang H; Wang Y; Li G; Geng Y; Hao Y; Zhang Z
    Front Oncol; 2021; 11():633032. PubMed ID: 33912454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.
    Kim BJ; Kim JH; Kim HS
    Oncotarget; 2017 Aug; 8(31):51779-51785. PubMed ID: 28881686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients.
    Vucinic D; Skocilic I; Golcic M; Dobrila-Dintinjana R; Kolak M; Jerkovic I; Tesar EC; Ferari AM; Redjovic A; Marusic J; Kolovrat D; Mikolasevic I
    J Pers Med; 2024 Mar; 14(3):. PubMed ID: 38541020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.
    Zhang H; Chen J; Zhang X; Zhu X; Wang Z; Sun G; Liang J; Chen Y; Shen Y; Liu J; Li X; Wei Q; Liu Z; Zeng H; Shen P
    Immunotherapy; 2022 Apr; 14(5):309-320. PubMed ID: 35187953
    [No Abstract]   [Full Text] [Related]  

  • 58. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Nov; 8(54):93149-93155. PubMed ID: 29190984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang L; Li L; Zhou Y; Yang Z; Wang M; Gao Y; Yang Y; Yang F; Liu B; Hong X; Chen G
    J Cancer; 2020; 11(24):7137-7145. PubMed ID: 33193876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.